Clinical trials: Kidney Insufficiency
Chronic Kidney Disease
Study to Compare Once A Day Sevelamer Dosing With Three Times Per Day Sevelamer Dosing
A randomized, cross-over, open-label study will be conducted to evaluate the equivalency, safety and tolerability of sevelamer once per day dosing, given with the largest meal, compared with standard three times per day dosing…
- Trial name
- NCT00324376
- Testing
- Sevelamer hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 24 people
- Sponsor
- Genzyme, a Sanofi Company
Chronic Kidney Disease
INCLUDE-CKD: INCLUsive Digital carE for Chronic Kidney Disease
This study will provide valuable insights into the demographics of MyRenalCare users, their digital adherence, and the overall impact of the app on health outcomes, healthcare costs, and environmental sustainability.
- Trial name
- INCLUDE-CKD (NCT07613593)
- Testing
- Non-Interventional Study
- Where
- United Kingdom
- Volunteers
- 1,000 people
- Sponsor
- Portsmouth Hospitals NHS Trust
Aspergillosis, Invasive Fungal Infections
Isavuconazole in the Treatment of Renally Impaired Aspergillosis and Rare Fungi
The purpose of this study is to investigate the efficacy and safety of isavuconazole in the treatment of renally impaired participants with invasive fungal infections caused by Aspergillus and participants with invasive fungal…
- Trial name
- VITAL (NCT00634049)
- Testing
- isavuconazole
- Where
- 96 sites in United States, Argentina and 17 more
- Volunteers
- 149 people
- Sponsor
- Astellas Pharma Inc
Mechanical Ventilation Complication, Arterial Thrombosis
Pragmatic Randomized Trial for Arterial Catheters in the Critical Care Environment
Investigators will conduct a pragmatic randomized trial to investigate the non-inferiority of restricted use of invasive arterial lines compared to standard arterial line use.
- Conditions
- Mechanical Ventilation Complication, Arterial Thrombosis, Limb Ischemia, Shock
- Trial name
- GRACE (NCT05411315)
- Testing
- Restricted-use of arterial catheter, Standard-use of arterial catheter
- Where
- United States
- Volunteers
- 700 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Cirrhosis, Liver, Acute-On-Chronic Liver Failure
Point-of-Care Echocardiography to Assess Impact of Dynamic Cardiac Function, Renal and Cardiac Biomarkers in Cirrhosis With Refractory Ascites
Point-of-care echocardiography (POC-Echo) is used to determine left ventricular systolic and diastolic dysfunction (LVDD), inferior vena cava (IVC) dynamics and volume status in cirrhosis and Acute-on-chronic liver failure ACLF…
- Conditions
- Cirrhosis, Liver, Acute-On-Chronic Liver Failure, Refractory Ascites, Ascites
- Trial name
- NCT05700708
- Testing
- Echocardiographic assessment
- Where
- India
- Volunteers
- 80 people
- Sponsor
- Post Graduate Institute of Medical Education and Research, Chandigarh
End-Stage Kidney Disease, Hemolysis
Fluid Distribution Timetable on Adherence to Fluid Restriction of Patients With End-Stage Renal Disease on Hemodialysis
Fluid restriction is necessary among patients with chronic kidney disease. However, treatment adherence remains a challenge. Hence, this study determined the effects of a fluid distribution timetable on adherence to fluid…
- Conditions
- End-Stage Kidney Disease, Hemolysis, Nursing
- Trial name
- NCT03582592
- Testing
- Fluid Distribution Timetable
- Volunteers
- 24 people
- Sponsor
- University of Santo Tomas Hospital, Philippines
Renal Impairment
A Study to Determine the Pharmacokinetics, Pharmacodynamics, and Tolerabiltiy of Betrixaban in Patients With Mild, Moderate, and Severe Renal Impairment
The purpose of the study is to compare the pharmacokinetics, pharmacodynamics, and tolerability of betrixaban in patients with mild, moderate, and severe renal impairment to healthy volunteers.
- Trial name
- NCT00999336
- Testing
- Betrixaban
- Where
- Germany
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Acute Kidney Failure, Critical Illness
Effect of Protein Dosage on Persistent Acute Renal Failure in Critically Ill Patients.
Background: Acute kidney injury (AKI) is common in critically ill patients and is associated with worse outcomes, including longer ICU stay, need for dialysis, and higher mortality.
- Conditions
- Acute Kidney Failure, Critical Illness, Protein Intake, Nutritional Support
- Trial name
- NCT07631221
- Where
- 6 sites in Argentina
- Volunteers
- 344 people
- Sponsor
- Hospital Italiano de Buenos Aires
Acute Kidney Injury
Ischemic Preconditioning to Prevent Acute Kidney Injury
The purpose of this study is to learn about the impact of ischemic preconditioning in reducing contrast induced kidney damage in people with pre-existing kidney problems who are undergoing cardiac catheterization procedures.
- Trial name
- NCT02167152
- Testing
- Ischemic preconditionin
- Where
- United States
- Volunteers
- 115 people
- Sponsor
- University of Kansas Medical Center
Transplant; Failure, Kidney, Renal Disease, End Stage
Oral Paricalcitol in Kidney Transplant Recipients
This study is being done to find out whether patients who receive a kidney transplant can benefit from taking the medication paricalcitol (trade name Zemplar®) as compared to kidney transplant recipients not taking this…
- Conditions
- Transplant; Failure, Kidney, Renal Disease, End Stage, Hyperparathyroidism, Secondary
- Trial name
- NCT00587158
- Testing
- Paricalcitol, Corticosteroid Avoidance Immune Suppression Protocol
- Where
- 2 sites in United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Cardiac Surgery, Aortocoronary Bypass
Remote Ischemic Preconditioning After Cardiac Surgery
Acute kidney injury (AKI) is a well-recognized complication after cardiac surgery with cardiopulmonary bypass (CPB). The aim of this study is to reduce the incidence of AKI by implementing remote ischemic preconditioning and to…
- Trial name
- RIPCRenal (NCT02997748)
- Testing
- Remote ischemic preconditioning (RIPC)
- Where
- Germany
- Volunteers
- 180 people
- Sponsor
- University Hospital Muenster
Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3
Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis)
This study is designed to establish the effect of 2 doses of vonafexor on the kidney. This will be investigated in subjects with mild or moderate reduced estimated glomerular filtration rate (eGFR) and suspected MASH.
- Conditions
- Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Metabolic Dysfunction-Associated Steatohepatitis
- Trial name
- MASH (NCT06939816)
- Testing
- Vonafexor low dose, Vonafexor high dose
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- Enyo Pharma
Kidney Disease, Chronic
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
This national study was a post-marketing surveillance study conducted in Korea from 29 August 2008 to 28 August 2012 to meet local regulatory requirements for Mircera (monopegylated-epoetin beta).
- Trial name
- NCT02263833
- Testing
- Mircera
- Where
- South Korea
- Volunteers
- 748 people
- Sponsor
- Hoffmann-La Roche
Diabetes Mellitus, Type 2
A Study of the Pharmacokinetics of Albiglutide in Normal and Renally Impaired Subjects.
The purpose of this study is to assess the pharmacokinetics and safety of a single subcutaneously injected dose of albiglutide in subjects with type 2 diabetes mellitus with varying degrees of renal function, including subjects…
- Trial name
- NCT00938158
- Testing
- albiglutide
- Where
- 7 sites in United States, South Africa
- Volunteers
- 75 people
- Sponsor
- GlaxoSmithKline
ESRD
Smell, Taste, Salivary Flow, and Oral Health in Patient Receiving Dialysis: A Before and After Study.
Studies show that the change of smell and taste, also dry mouth are the most common symptoms in end stage renal disease patients, the accumulation of uremic toxins would damage the intrinsinc antioxidant systems of the olfactory…
- Trial name
- NCT04401358
- Where
- Taiwan
- Volunteers
- 75 people
- Sponsor
- National Taiwan University Hospital
Hyperlipidemias
A Study of HRS-1301 Tablets in Healthy Subjects and Those With Impaired Kidney Function
The primary objective of this study is to evaluate pharmacokinetics of HRS-1301 tablets in subjects with impaired kidney function in comparison with healthy subjects, to develop dose recommendations for patients with renal…
- Trial name
- NCT07322016
- Testing
- HRS-1301 Tablet
- Where
- China
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Shandong Suncadia Medicine Co., Ltd.
Coronary Heart Disease, Stroke
Long-term Effects of Intensive Insulin Treatment in Type 1 Diabetes
To investigate long-term effects on cardiovascular mortality/morbidity and renal failure in type 1 diabetes patients former randomized to intensive insulin treatment
- Conditions
- Coronary Heart Disease, Stroke, Renal Failure
- Trial name
- SDIS (NCT02138006)
- Testing
- Intensive insulin treatment, Standard insulin treatment
- Where
- Sweden
- Volunteers
- 102 people
- Sponsor
- Karolinska Institutet
Chronic Kidney Diseases
Role of AST120 for Sarcopenia Prevention in Pre-dialysis Chronic Kidney Disease
This study is to assess the effect of 48 weeks administration of Renamezin capsule on prevention of sarcopenia in pre-dialysis patients with chronic kidney disease.
- Trial name
- RECOVERY (NCT03788252)
- Testing
- Renamezin
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Gumi Cha Medical Center
Arteriovenous Graft, Arteriovenous Fistula
Validation of Arterio Venous Access Stage (AVAS) Classification
VAVASC trial is an observational multicentre study. The aim of this trial is to validate AVAS (arteriovenous vascular access stage) classification.
- Conditions
- Arteriovenous Graft, Arteriovenous Fistula, Dialysis Access Malfunction, Kidney Failure
- Trial name
- VAVASC (NCT04796558)
- Testing
- AVAS Classification
- Where
- Czechia
- Volunteers
- 800 people
- Sponsor
- Vascular surgery, University hospital Královské Vinohrady, Prague
Renal Insufficiency
PF-04634817 Renal Impairment Study
Patients with renal impairment are the target population for PF-04634817. The clearance mechanism of this drug means that exposure may be increased in subjects with renal impairment.
- Trial name
- NCT01791855
- Testing
- PF-04634817
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.